nayan patel glutathione Episode 85 Featuring World Renown Expert Dr. Patel! Get ready to become a full blown expert on everything Glutathione! Last year at A4M, I was heading to see a speaker 454: Nayan Patel | Unlocking

Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]

For 5-amino-1MQ specifically: Preclinical studies have not prominently described heart rate elevation as a dominant signal The mechanism (NNMT inhibition, NAD+ preservation) does not have the same direct cardiac implications as nuclear receptor agonism Human cardiovascular data at clinically relevant exposures are limited For physicians, the current evidence base does not support a major cardiovascular safety flag, but the limited human dataset means confident statements are premature

Clinical trials show oral glutathione at 500mg doses reduces melanin index when taken consistently for 8-12 weeks

NNMT inhibitors should reduce NNMT activity in aged muscles such that the NAD+ salvage cycle in aged muscle cells is returned to the functioning observed in young muscle cells

Though not currently approved for human use, the MOTS-C peptide is becoming popular for its energy-boosting effect and is often part of peoples longevity or metabolic health stacks

Pharmaceutics , 15